Articles

Market access for new specialist drugs will get harder, says NHS Engla…

2nd July 2015

Market access for new specialist drugs will get harder, says NHS England

Andrew McConaghie reports on a frank exchange of views about NHS finances and market access in the UKPharma's late-stage pipeline may be dominated by a new generation of specialist, often groundbreaking... Read more

Gathering real-world evidence in the early access setting

1st July 2015

Gathering real-world evidence in the early access settingStuart Bell

Early access programmes offer the potential for gaining real-world evidence in the period between phase III and marketing authorisation, which could provide data to support the product's effectiveness and value... Read more

Pharma: shouldn't every day be Social Media Day?

30th June 2015

Pharma: shouldn't every day be Social Media Day?Christian Gardner

Christian Gardner, Director, Media Services at pharmaphorum marks Social Media Day by looking at pharma's progress in engaging patients and healthcare professionals via social media. Did you know that today is... Read more

IMS Health UK Market Access Summit 2015

29th June 2015

IMS Health UK Market Access Summit 2015

18.12 BST And with that Angela McFarlane brings things to a close with a brief summary and some recommendations - increased transparency of process and mandates of roles for the NHS, for the... Read more

News

Boehringer secures first European approvals for new COPD treatment

2nd July 2015

Boehringer secures first European approvals for new COPD treatmentClaire Bowie

Boehringer Ingelheim has secured first European approvals for its new once-daily treatment for chronic obstructive pulmonary disease, Spiolto Respimat. The drug combines the long-acting muscarinic agonist tiotropium - the active ingredient... Read more

Novo Nordisk pulls Tresiba from Germany in protest at pricing

2nd July 2015

Novo Nordisk pulls Tresiba from Germany in protest at pricingStaff reporter

Novo Nordisk has become the latest drugmaker to refuse to supply one of its diabetes products in Germany after failing to agree a price with the national body representing health... Read more

UK backs early access to BMS’s Opdivo for lung cancer

1st July 2015

UK backs early access to BMS’s Opdivo for lung cancerStaff reporter

Patients with lung cancer in the UK can now get treatment with Bristol-Myers Squibb's Opdivo under a new scheme designed to accelerate access to new drugs.Opdivo (nivolumab) has been included... Read more

Celgene pays $1bn for stake in CAR-T specialist Juno

30th June 2015

Celgene pays $1bn for stake in CAR-T specialist JunoStaff reporter

US firm Celgene is desperate not to be left out of the race to develop chimeric antigen receptor T cells (CAR-T) for cancer, paying $1 billion for a slice of... Read more

Audio & Video

Live webinar 9th July – Changing behavio…

BrightTALK holding slide 4 22June

 

Understanding your customers is fundamental to effective communication. Current segmentation strategies draw on ever more detailed information... View more

Available on demand: Effectively using r…

Zephyr-Webinar-Holding-Slide-2

 

Life sciences companies need to make better use of the insights that real-world data (RWD) can provide in order to improve market... View more

Available on demand: Exclusive debate/we…

Ashfield-PP-HS1

 

The way that physicians want and need to consume information has changed dramatically over recent years and continues to evolve rapidly. Working in... View more

Being Patient-centric is being Family-ce…

 

Cancer survivor and patient opinion leader Andrew Schorr and his wife Esther Schorr discuss how families should be involved in decision-making around care for patients.... View more

White Papers

Optimising patient outcomes through phys…

Optimising patient outcomes through physician educationDr James Quekett

Physician education is undergoing a massive change as the volume of advances in therapies and practices increases and the use of digital channels facilitates new forms of scientific exchange. This white... View info

Is pharma brand marketing dead?

Is pharma brand marketing dead?Mark Sales, Fabrice Bourg & Richard Goosey

This comprehensive supplement brings together a series of articles, insights and discussions produced by Kantar Health in order to help stimulate debate and fresh thinking about the future of pharmaceutical... View info

Improved health and wellbeing in COPD

Improved health and wellbeing in COPDAna Maria Arboleda, Clare Maloney & Prof John Weinman

Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disorder, which, as it progresses, places a significant burden on individuals and those caring for them. This is not only... View info

Computer Gaming: The Future of Decision-…

Computer Gaming: The Future of Decision-Making for Life Sciences?

How can life science brands identify winning strategic decisions when there are so many variables to consider? One route is via 'road-testing' decisions ahead of sign-off under computer game simulated... View info

Further News & Articles

Opdivo first PD-1 treatment to gain European approval

Bristol-Myers Squibb (BMS) has scored a victory over its rival Merck by gaining the first European approval in t... Read more

News

UK first to offer routine meningitis B vaccination

All babies in England and Scotland will be offered meningitis B (MenB) vaccines from September, as disputes over... Read more

News

UK pharma disclosure of payments: lessons from the US Sunshine Act

In the second article on pharma's disclosure of payments in the UK, Andrew McConaghie talks to the PMCPA's Heathe... Read more

Articles

NICE asks for more information on Gilead's Zydelig

The National Institute for Health and Care Excellence (NICE) has rejected Gilead Sciences' chronic lymphocytic l... Read more

News

Oncology opinion leaders debate NHS issues

Medical, political and patient organisation specialists were put through their paces on topics affecting delivery... Read more

Articles

Novartis to highlight ageing research at US investor day

Novartis will describe to investors later today how it is developing a series of therapies for diseases of old a... Read more

News